Martin P. Schwalm

Max Von Laue Str. 15
Frankfurt Am Main, HE 60438, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Utilization of Functional Degradation Pathways for the Characterization of Ubiquitin-Proteasome System Tool Compounds.

Utilization of Functional Degradation Pathways for the Characterization of Ubiquitin-Proteasome System Tool Compounds.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: August 10, 2026

Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors.

Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors.

Journal: Journal of medicinal chemistry

Published: July 13, 2026

On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases.

On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases.

Journal: Journal of medicinal chemistry

Published: June 17, 2026

p21-Activated Kinase (PAK) Group I-Targeting Inhibitors Promote the Dimeric Conformation in Live Cells.

p21-Activated Kinase (PAK) Group I-Targeting Inhibitors Promote the Dimeric Conformation in Live Cells.

Journal: ACS chemical biology

Published: June 13, 2026

Identification and Validation of 3-Cyano-Quinoline Ligands Targeting Integrin-Linked Kinase (ILK).

Identification and Validation of 3-Cyano-Quinoline Ligands Targeting Integrin-Linked Kinase (ILK).

Journal: Journal of medicinal chemistry

Published: May 26, 2026

Small-molecule modulators of HIPK4 activity and proteostasis.

Small-molecule modulators of HIPK4 activity and proteostasis.

Journal: bioRxiv : the preprint server for biology

Published: May 25, 2026

Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib leads to Potent and Selective Quinoline-based HIPK4 Inhibitor AZ137.

Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib leads to Potent and Selective Quinoline-based HIPK4 Inhibitor AZ137.

Journal: bioRxiv : the preprint server for biology

Published: May 04, 2026

Structure Merging Approach Leads to New Dual Potent and Selective USP25/USP28 Inhibitors.

Structure Merging Approach Leads to New Dual Potent and Selective USP25/USP28 Inhibitors.

Journal: Journal of medicinal chemistry

Published: April 22, 2026

Click. Screen. Degrade. A Miniaturized D2B Workflow for Rapid PROTAC Discovery.

Click. Screen. Degrade. A Miniaturized D2B Workflow for Rapid PROTAC Discovery.

Journal: Journal of medicinal chemistry

Published: January 23, 2026

Un-LOK-ing a New Approach for Conformational Selective Targeting of STK10 (LOK).

Un-LOK-ing a New Approach for Conformational Selective Targeting of STK10 (LOK).

Journal: ACS medicinal chemistry letters

Published: August 06, 2025

Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors.

Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors.

Journal: Nature communications

Published: July 03, 2025

Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective Inhibitor.

Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective Inhibitor.

Journal: Journal of medicinal chemistry

Published: July 02, 2025

Showing 1-12 of 46

Last Updated: 09/26/2026